Bio-Techne (TECH) Stock: Buy, Sell, or Hold?
TECH - Bio-Techne Corp.
$72.40
0.00 (0.00%)
▲
5d:
-0.29%
30d:
+0.14%
90d:
+2.09%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When TECH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TECH trades at premium valuation expecting 12.1% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: TECH trades at premium valuation expecting 12.1% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$30.06
Based on -6.4% avg growth
INTRINSIC VALUE TODAY
$18.67
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TECH is currently trading at $72.40, which is considered fair relative to its 30-day fair value range of $72.26 to $72.50. From a valuation perspective, the stock is trading at a premium (Forward PE: 42.6) compared to its historical average (30.3). At these levels, the market is pricing in 12.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TECH is in a strong uptrend. The price is currently testing key support at $72.33. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TECH scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TECH is in a strong uptrend. The price is currently testing key support at $72.33. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TECH scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$72.26 -
$72.50
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
78.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($70.50)
- NEUTRAL: PE elevated vs history but 12.1% growth expectation is conservative given 129% recent growth
- CAUTION: Bottoming setup, but lagging the sector by 14% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$72.26 -
$72.50
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$72.33
Resistance Level
$72.69
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.59
Wall Street Target
$70.50
(-2.6%)
Revenue Growth (YoY)
1.3%
Earnings Growth (YoY)
128.6%
Profit Margin
15.0%
Valuation Premium vs History
+12.1% premium
PE vs Historical
42.6 vs 30.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.1%
(market-implied from PE analysis)
1-Year Target
$81.16
(+12%)
2-Year Target
$90.98
(+26%)
3-Year Target
$101.99
(+41%)
3-Yr Target (if PE normalizes)
(PE: 43→30)
PE COMPRESSION
$72.56
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 42.6, Growth: -16.8%)
$52.78
(+-27%)
Base:
(SPY PE: 20.4, Growth: -16.8%)
$25.28
(-65%)
Bear:
(PE: 17.3, Growth: -16.8%)
$21.49
(-70%)
📈
Valuation based on Current Earnings
Forward PE: 34.60 | Forward EPS (Implied): $2.09
Bull Case
$87.42
(+21%)
Analyst growth 15.0%, PE expands to 36.3
Base Case
$72.40
(0%)
Market implied 0.0%, PE stable at 34.6
Bear Case
$55.39
(-24%)
Severe decline -15.0%, PE contracts to 31.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 4:58 PM ET
Data refreshes hourly during market hours. Next update: 5:58 PM
Data refreshes hourly during market hours. Next update: 5:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
